<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36324055</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>IgG autoantibodies against ACE2 in SARS-CoV-2 infected patients.</ArticleTitle><Pagination><StartPage>e28273</StartPage><MedlinePgn>e28273</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e28273</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.28273</ELocationID><Abstract><AbstractText>How frequently autoantibodies against angiotensin-converting enzyme 2 (ACE2) occur in patients infected by SARS-CoV-2 is understudied and limited to investigations on a small sample size. The presence of these antibodies may contribute to the long-lasting effects of COVID-19 observed in some individuals, particularly if IgG-class antibodies would emerge in patients. This study assessed the prevalence of IgG autoantibodies against ACE2 in 1139 patients infected with SARS-CoV-2 and examined their relationship with severity, demographic characteristics, and status of vaccination against influenza. The overall prevalence of anti-ACE IgG antibodies in our cohort was 1.5%. Most of these individuals were men (76.5%) and underwent mild COVID-19, but some severe and asymptomatic cases were also observed. Patients with severe infection had twofold higher titers than mild and asymptomatic cases. Age, comorbidities, and influenza vaccination status were not related to antibody prevalence. The prevalence of IgG anti-SARS-CoV-2 antibodies (against nucleocapsid protein and S2 subunit, but not against receptor-binding domain) was higher in the subset with ACE2 autoantibodies. Further research is required to understand the potential spectrum and duration of effects of IgG autoantibodies against ACE2 in patients after SARS-CoV-2 infection, particularly concerning long COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hallmann</LastName><ForeName>Ewelina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Influenza Research, National Influenza Center at the National Institute of Public Health NIH - National Research Institute in Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sikora</LastName><ForeName>Dominika</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Environmental Medicine, Pozna&#x144; University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Doctoral School, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poniedzia&#x142;ek</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Environmental Medicine, Pozna&#x144; University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szyma&#x144;ski</LastName><ForeName>Karol</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Influenza Research, National Influenza Center at the National Institute of Public Health NIH - National Research Institute in Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondratiuk</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Influenza Research, National Influenza Center at the National Institute of Public Health NIH - National Research Institute in Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x17b;urawski</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunobiology, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brydak</LastName><ForeName>Lidia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Influenza Research, National Influenza Center at the National Institute of Public Health NIH - National Research Institute in Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rzymski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4713-0801</Identifier><AffiliationInfo><Affiliation>Department of Environmental Medicine, Pozna&#x144; University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Science Association, Universal Scientific Education and Research Network, Poznan, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">autoantibody</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">renin-angiotensin system</Keyword></KeywordList><CoiStatement>The authors declare no conflict&#xa0;of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36324055</ArticleId><ArticleId IdType="pmc">PMC9877908</ArticleId><ArticleId IdType="doi">10.1002/jmv.28273</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nat&#xa0;Med. 2021;27(4):601&#x2010;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post COVID&#x2010;19 condition or long COVID: a meta&#x2010;analysis and systematic review. J Infect Dis. 2022;226:1593&#x2010;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM. The costs of long COVID. JAMA Health Forum. 2022;3(5):e221809.</Citation><ArticleIdList><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton A, Olliaro P, Sigfrid L, et al. Long COVID: tackling a multifaceted condition requires a multidisciplinary approach. Lancet Infect Dis. 2021;21(5):601&#x2010;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906694</ArticleId><ArticleId IdType="pubmed">33548193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G&#x2010;protein coupled receptors in patients with persistent Long&#x2010;COVID&#x2010;19 symptoms. J Transl Autoimmun. 2021;4:100100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M, Rodr&#xed;guez Y, Acosta&#x2010;Ampudia Y, et al. Autoimmunity is a hallmark of post&#x2010;COVID syndrome. J Transl Med. 2022;20(1):129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="pubmed">35296346</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS&#x2010;CoV&#x2010;2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4):102792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur JM, Forrest JC, Boehme KW, et al. Development of ACE2 autoantibodies after SARS&#x2010;CoV&#x2010;2 infection. PLoS One. 2021;16(9):e0257016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8415618</ArticleId><ArticleId IdType="pubmed">34478478</ArticleId></ArticleIdList></Reference><Reference><Citation>Casciola&#x2010;Rosen L, Thiemann DR, Andrade F, et al. IgM anti&#x2010;ACE2 autoantibodies in severe COVID&#x2010;19 activate complement and perturb vascular endothelial function. JCI Insight. 2022;7(9):e158362. 10.1172/jci.insight.158362</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.158362</ArticleId><ArticleId IdType="pmc">PMC9090251</ArticleId><ArticleId IdType="pubmed">35349483</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladjemi MZ. Anti&#x2010;idiotypic antibodies as cancer vaccines: achievements and future improvements. Front Oncol. 2012;2:158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490135</ArticleId><ArticleId IdType="pubmed">23133825</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenmann J. Speculations on idiotypes and homobodies. Ann Immunol. 1973;124(2):171&#x2010;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">4126980</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner AJ. ACE2 cell biology, regulation, and physiological functions. The Protective Arm of the Renin Angiotensin System (RAS). Elsevier; 2015:185&#x2010;189.</Citation></Reference><Reference><Citation>Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS&#x2010;COV&#x2010;2. Front Cell Infect Microbiol. 2020;10:317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7294848</ArticleId><ArticleId IdType="pubmed">32582574</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweitzer KS, Crue T, Nall JM, et al. Influenza virus infection increases ACE2 expression and shedding in human small airway epithelial cells. Eur Respir J. 2021;58(1):2003988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8378143</ArticleId><ArticleId IdType="pubmed">33419885</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, Haga S, Ishizaka Y, Mimori A. Autoantibodies to angiotensin&#x2010;converting enzyme 2 in patients with connective tissue diseases. Arthritis Res Ther. 2010;12(3):R85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911869</ArticleId><ArticleId IdType="pubmed">20470389</ArticleId></ArticleIdList></Reference><Reference><Citation>Pel&#xe0; G, Goldoni M, Solinas E, et al. Sex&#x2010;related differences in long&#x2010;COVID&#x2010;19 syndrome. J Womens Health. 2022;31(5):620&#x2010;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">35333613</ArticleId></ArticleIdList></Reference><Reference><Citation>Malki MI. COVID&#x2010;19 and male infertility: an overview of the disease. Medicine. 2022;101(27):e29401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258969</ArticleId><ArticleId IdType="pubmed">35801743</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizio&#x142;ek B, Sie&#x144;czyk M, Grzywa R, et al. The prevalence and role of functional autoantibodies to angiotensin&#x2010;converting&#x2010;enzyme&#x2010;2 in patients with systemic sclerosis. Autoimmunity. 2021;54(4):181&#x2010;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">33910447</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomic Epidemiology of SARS&#x2010;CoV&#x2010;2 with Subsampling Focused Globally since Pandemic Start. Accessed October 3, 2022. https://nextstrain.org/ncov/gisaid/global/
</Citation></Reference><Reference><Citation>Cantuti&#x2010;Castelvetri L, Ojha R, Pedro LD, et al. Neuropilin&#x2010;1 facilitates SARS&#x2010;CoV&#x2010;2 cell entry and infectivity. Science. 2020;370(6518):856&#x2010;860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>